                         SEQUENCE LISTING

<110>  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW 
       UNIVERSITY OF JERUSALEM LTD.
 
<120>  SOMATOSTATIN PRODRUGS

<130>  Yissum0148PCT

<150>  US 62/560,216
<151>  2017-09-19

<160>  23    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  D-Phe

<220>
<221>  DISULFID
<222>  (2)..(7)
<223>  bridge

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  (ol) = alcohol C termuinus

<400>  1

Phe Cys Phe Trp Lys Thr Cys Thr 
1               5               


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  X = D-2 naphthylalanine

<220>
<221>  DISULFID
<222>  (2)..(7)
<223>  bridge

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  AMIDATION

<400>  2

Xaa Cys Tyr Trp Lys Val Cys Thr 
1               5               


<210>  3
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  4Abu, GABA

<220>
<221>  MOD_RES
<222>  (1)..(8)
<223>  backbone-to-end cyclization between the 
       N-alpha-omega-functionalized derivative of GlyC3 and the 
       N-terminus

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  AMIDATION

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  GlyC3 building unit

<400>  3

Xaa Phe Trp Trp Lys Thr Phe Gly 
1               5               


<210>  4
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  (2-aminoethyl-carbamoyl)-Hydroxyproline

<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  head-to-tail cyclization

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  PhenylGlycine, Phg

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  Tyr(Bzl)

<400>  4

Xaa Xaa Trp Lys Tyr Phe 
1               5       


<210>  5
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  5

Phe Trp Lys Thr 
1               


<210>  6
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  D-Trp

<400>  6

Phe Trp Lys Thr 
1               


<210>  7
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  head-to-tail-cyclization

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-Trp

<400>  7

Pro Phe Trp Lys Thr Phe 
1               5       


<210>  8
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  head-to-tail cyclization

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  N-methyl D-Trp

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methyl Lys

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  N-methyl Phe

<400>  8

Pro Phe Trp Lys Thr Phe 
1               5       


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheN2 building unit

<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X6

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  PheC3 building unit

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  9

Phe Tyr Trp Lys Val Phe Thr 
1               5           


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheC3 building unit

<220>
<221>  MOD_RES
<222>  (1)..(9)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X9

<220>
<221>  DISULFID
<222>  (2)..(7)
<223>  bridge

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  PheN3 building unit

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  AMIDATION

<400>  10

Phe Cys Phe Trp Lys Thr Cys Phe Phe 
1               5                   


<210>  11
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  N-METHYL D-Trp

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  N-METHYL Lys

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-METHYL Phe

<400>  11

Trp Lys Thr Phe 
1               


<210>  12
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  head-to-tail cyclization

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  N-methyl D-Trp

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  N-methyl Lys

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  N-methyl Phe

<400>  12

Phe Trp Trp Lys Thr Phe 
1               5       


<210>  13
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  Backbone-to-end cyclization between the 
       N-alpha-omega-functionalized derivative of X6 and the N terminus

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  D-Lys

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  PheC2 building unit

<400>  13

Phe Phe Phe Trp Lys Phe 
1               5       


<210>  14
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheC1 building unit

<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X6

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  PheN2 building unit

<400>  14

Phe Phe Phe Trp Lys Phe 
1               5       


<210>  15
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheC1 building unit

<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X6

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  D-Lys

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  PheN2 building unit

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  AMIDATION

<400>  15

Phe Phe Phe Trp Lys Phe 
1               5       


<210>  16
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheN2 building unit

<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X6

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-2-naphtylalanine

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  GlyC2 building unit

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  16

Phe Tyr Xaa Lys Val Gly Thr 
1               5           


<210>  17
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheN2 building unit

<220>
<221>  MOD_RES
<222>  (1)..(6)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X6

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  GlyC2 building unit

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  2-naphtylalanine

<400>  17

Phe Tyr Trp Lys Val Gly Xaa 
1               5           


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheN2 building unit

<220>
<221>  MOD_RES
<222>  (1)..(7)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X7

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  GlyC2 building unit

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  18

Phe Tyr Trp Lys Val Val Gly 
1               5           


<210>  19
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheN2 building unit

<220>
<221>  MOD_RES
<222>  (1)..(7)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X7

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  Naphtylalanine

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  GlyC2 building unit

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  19

Phe Tyr Trp Lys Ser Xaa Gly 
1               5           


<210>  20
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  PheN2 building unit

<220>
<221>  MOD_RES
<222>  (1)..(7)
<223>  backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X1 and the N-alpha-omega-functionalized derivative 
       of X7

<220>
<221>  MOD_RES
<222>  (3)..(3)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (6)..(6)
<223>  2-naphtylalanine

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  GlyC2 building unit

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  AMIDATION

<400>  20

Phe Phe Trp Lys Thr Xaa Gly 
1               5           


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(8)
<223>  backbone cyclization with disulfide bond between the 
       N-alpha-omega-S-functionalized derivative of X8 and the side 
       chain of the X1 Cysteine

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  GlyS2 building unit

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  AMIDATION

<400>  21

Cys Phe Trp Trp Lys Thr Phe Gly 
1               5               


<210>  22
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  D-Phe

<220>
<221>  MOD_RES
<222>  (2)..(9)
<223>  Backbone cyclization with disulfide bridge between the 
       N-alpha-omega-S-functionalized derivative of X9 and the side 
       chain of the X2 Cys residue

<220>
<221>  MOD_RES
<222>  (5)..(5)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  GlyS2 building unit

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  AMIDATION

<400>  22

Phe Cys Phe Trp Trp Lys Thr Phe Gly 
1               5                   


<210>  23
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  CARBOHYD
<222>  (1)..(1)
<223>  Galactose

<220>
<221>  MOD_RES
<222>  (1)..(1)
<223>  Dbu - 2,4 diaminobutiric acid

<220>
<221>  MOD_RES
<222>  (1)..(8)
<223>  Backbone cyclization between the N-alpha-omega-functionalized 
       derivative of X8 and the free amino group of X1

<220>
<221>  MOD_RES
<222>  (4)..(4)
<223>  D-Trp

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  GlyC3 building unit

<220>
<221>  MOD_RES
<222>  (8)..(8)
<223>  AMIDATION

<400>  23

Xaa Phe Trp Trp Lys Thr Phe Gly 
1               5               


